These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27687312)

  • 1. PARP inhibition in BRCA2-mutated prostate cancer.
    Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
    [No Abstract]   [Full Text] [Related]  

  • 2. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    Helleday T
    Ann Oncol; 2016 May; 27(5):755-7. PubMed ID: 26865580
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 5. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    Romero-Laorden N; Piñeiro-Yañez E; Gutierrez-Pecharroman A; Pacheco MI; Calvo E; Al-Shahrour F; Castro E; Olmos D
    Ann Oncol; 2017 May; 28(5):1158-1159. PubMed ID: 28453706
    [No Abstract]   [Full Text] [Related]  

  • 7. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in castration-resistant prostate cancer.
    Tripathi A; Balakrishna P; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    Schweizer MT; Cheng HH; Nelson PS; Montgomery RB
    J Clin Oncol; 2020 Nov; 38(32):3740-3742. PubMed ID: 32897829
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Response to Olaparib in a Patient With Leptomeningeal Carcinomatosis in Newly Diagnosed Breast Cancer With Germline
    Shah M; Green J; Hudacko R; Cohen AJ
    JCO Precis Oncol; 2024 Jul; 8():e2400063. PubMed ID: 38991180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Kwon DH; Booth CM; Prasad V
    Eur Urol; 2021 Jun; 79(6):710-712. PubMed ID: 33722420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
    Sandhu SK; Omlin A; Hylands L; Miranda S; Barber LJ; Riisnaes R; Reid AH; Attard G; Chen L; Kozarewa I; Gevensleben H; Campbell J; Fenwick K; Assiotis I; Olmos D; Yap TA; Fong P; Tunariu N; Koh D; Molife LR; Kaye S; Lord CJ; Ashworth A; de Bono J
    Ann Oncol; 2013 May; 24(5):1416-8. PubMed ID: 23524863
    [No Abstract]   [Full Text] [Related]  

  • 17. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365755
    [No Abstract]   [Full Text] [Related]  

  • 18. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
    Gornstein EL; Sandefur S; Chung JH; Gay LM; Holmes O; Erlich RL; Soman S; Martin LK; Rose AV; Stephens PJ; Ross JS; Miller VA; Ali SM; Blau S
    Clin Breast Cancer; 2018 Apr; 18(2):184-188. PubMed ID: 29325860
    [No Abstract]   [Full Text] [Related]  

  • 19. PARP Inhibitors in Prostate Cancer.
    Grewal K; Grewal K; Tabbara IA
    Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    Simmons AD; Nguyen M; Pintus E
    BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.